Anti-Human CD339/JAG1 Recombinant Antibody (B70) (HX118107)

Name: Anti-Human CD339/JAG1 Recombinant Antibody (B70)
Brand: abinScience
SKU: HX118107
Price: 191 USD
Availability: InStock

Price(USD):

Spec:

Number:

Get quote

Overview

Catalog No.	HX118107
Species reactivity	Human, Mouse
Applications	FCM
Host species	Mouse
Isotype	IgG1, kappa
Clone ID	B70
Clonality	Monoclonal
Target	JAG1, Jagged1, CD339, JAGL1, Protein jagged-1, hJ1
Endotoxin level	Please contact with the lab for this information.
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P78504
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Background	Protein jagged-1 (CD339/JAG1) is a ~133 kDa protein. Ligand for multiple Notch receptors and involved in the mediation of Notch signaling. May be involved in cell-fate decisions during hematopoiesis. Seems to be involved in early and late stages of mammalian cardiovascular development. Inhibits myoblast differentiation. Enhances fibroblast growth factor-induced angiogenesis (in vitro). 1. Cordle, J. et al. (2008) Nature structural & molecular biology 15, 849-57. PMID: 18660822 2. Bauer, RC. et al. (2010) Human mutation 31, 594-601. PMID: 20437614 3. Li, L. et al. (1998) Immunity 8, 43-55. PMID: 9462510
Note	For research use only.

Images

References

Datasheet

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Overview